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Abstract
i
The importance o f  folate in norm al fetal developm ent and  wellbeing has been recognized only during  the past three decades and 
knowledge concerned is still far from com plete. In m an, folate acts as a substra te  in the transfer o f one-carbon moieties and thereby, 
plays an essential ro le in the synthesis o f  several am ino acids such as m ethionine and nucleic acids. Consequently, folate require­
ments are related to the am ount o f tissue growth. Epidemiological, clinical and  teratological research showed tha t this B-vitamin 
is particularly involved in the prevention and  pathogenesis o f  neural tube defects. Therefore, in this review the m etabolism  o f  folate 
has been outlined. Furtherm ore, the characteristics o f the various genically determ ined folate ‘deficiencies5 as well as a possible 
biochemical explanation  o f  the  relationship between folate and  neural tube  defects are being discussed. Finally, the new recom m en­
dations launched in N ovem ber 1993 by the D utch  H ealth  Council as well as the  F ood  and  N u trition  Council with regard to folate 
supplementation in  the prevention o f  neural tube defects are  presented.
Keywords: Folate; N eural tube defects; Prevention; Biochemistry; R ecom m endations
1. Introduction
Maternal folate status is important in the prevention 
and pathogenesis of neural tube defects (NTDs) [1]. It
is, however, unclear which precise mechanisms are in­
volved. Pregnant women are prone to develop a folate 
deficiency, probably due to their increased folate 
demands for the growing fetal and maternal tissues. 
Other factors provoking folate deficiency include a poor 
diet, the physiological haemodilution o f pregnancy, in­
creased plasma clearance and hormonal influences [2], 
Our hypothesis is that a subset o f NTDs might be due 
to a disbalance in the maternal and/or embryonic 
homocysteine metabolism, partly genically determined, 
in which folate plays a particularly important role [3,4].
Therefore, in the first part of this review, attention is 
given to the biochemistry and daily requirements o f  
folate, the diagnosis of folate deficiency and the genetic 
disorders in folate metabolism. In the second part, a 
possible underlying mechanism will be described which
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may explain (in part) the beneficial effect of folate sup­
plementation in the prevention of NTDs. Finally, new 
recommendations regarding folate supplementation are 
presented.
2. Folate
2,L Structure
In 1930, folic acid was first recognized as a factor 
present in the yeast preparation marmite, which was 
able to cure a megaloblastic anaemia occurring among 
Hindu women in India, particularly during pregnancy 
[5]. The term ‘folic acid5 (Latin folium, ‘leaf) for 
pteroyl-glutamic acid was introduced in 1941, and the 
substance was successfully synthesized in the form of 
pteroylmonoglutamate a couple of years later. Folic 
acid and folate are the preferred synonyms for 
pteroylglutamic acid (Fig. 1).
Folic acid comprises a pteridine, p-aminobenzoic acid 
and glutamic acid. The natural-occurring folates consist 
of a large group of derivatives derived from the reduc­
tion and addition to the basic structure. Folates are 
available in part as small molecules with one to three
0028-2243/95/509.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved 
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Fig. 1. The structure of folic acid and its derivatives (modified from
Rosenblatt [9]).
sidechains, i.e. mono and oligoglutamates, and in part 
as larger molecules, i.e. polyglutamates. Folates are 
present in all body tissues. Folate is stored to the great­
est extent in the polyglutamate form in liver, pancreas, 
kidneys and brain. Mono and oligoglutamates (free
folate) and polyglutamates together represent ‘total 
folate’.
2.2. Biochemistry o f  folate
Transport mechanism. The absorption process of 
dietary folate (mainly as 5-methylpteroylpolygluta- 
mates) is divided in two steps (Fig. 2). In the first step, 
polyglutamates are converted to monoglutamates by a 
conjugase present in the jejunum. Only monoglutamates 
or, at most oligoglutamate derivatives are taken up by
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Fig. 2 . Summary of digestion and absorption of folic acid and dietary 
folate derivatives by the intestinal cell (modified from Rowe [63]).
the intestinal cell The second step includes absorption 
by active as well as passive transport of monoglutamates
into the intestinal cell. In the intestinal cell, the absorbed 
monoglutamates are fully reduced to tetrahydrofolate 
(THF) by dihydrofolate reductase. Depending upon 
folate supply they are transported directly into the por­
tal circulation, converted to 5-methyltetrahydrofolate 
(5-methyl-THF), and transported to the portal circula­
tion, or converted directly into THF-polyglutamate 
stores.
The stored THF-polyglutamates can be degraded to 
THF-monoglutamates by intracellular conjugase and 
released into the circulation. 5-methyl-THF-monogluta- 
mate is the predominant form of folate in serum and in 
many tissues. In the liver, polyglutamate derivatives o f  
5-methyl-THF are the major stored folates.
About two-thirds of 5-methyl-THF in serum is loose­
ly bound to a non-specific low-affinity folate binder 
such as albumin. A second folate binder has also been 
described. Although this binder has a high affinity for
*
folate, its capacity is low. This protein may represent a 
storage form [6]. Blood of the umbilical cord contains 
both low and high-affinity folate binders [7], Folate 
binding proteins are involved in the transfer o f  folate 
against a concentration gradient from the mother to the 
fetus, which suggests active placental transport by which 
the fetus is able to accumulate folate. Strelling [8] deter­
mined higher folate levels in fetal blood as compared 
with maternal blood. The placenta seems able to supply 
the fetus with adequate folate. However, little is known
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about folate provision for the growth of the conceptus 
before the placenta has developed.
Metabolism. The prime function o f folate is to provide 
one-carbon moieties for the synthesis of three of the four 
bases of DNA, i.e. guanine, adenine and thymine, as well 
as for synthesis o f  other compounds. These one-carbon 
moieties are formate required for the synthesis of the 
purines 5-formamidoimidazole-4-carboxamide ribo­
nucleotide (FAICAR) and formylglycinamide ribonuc­
leotide (FGAR), methylene for deoxythymidine synthesis 
(dTMP), and the methyl group for methionine synthesis 
[9,10], The one-carbon moiety is derived from the con­
version of serine into glycine, formiminoglutamic acid 
(FiGlu) into glutamic acid (Glu), or the cleavage o f gly­
cine. The folate metabolism in man is depicted in Fig, 3.
The vitamin B12-dependent enzyme 5-methyl-THF- 
homocysteine methyl-transferase or methionine synthase 
(EC 2.1.1.13) catalyses the conversion o f 5-methyl-THF 
and homocysteine into THF and methionine. Methionine 
reacts with adenosine to form S-adenosylmethionine. S- 
Adenosylmethionine is the most important methyl donor 
and regulates its own synthesis by inhibition of 5,10- 
methylene-THF reductase (EC 1.1.1.68) and stimulation
of cystathionine synthase (EC 4.2.1.22) [11].
Methionine synthase requires reduced vitamin B12, i.e. 
methylcobalamin, as a cofactor. Cobalamin accepts its 
methyl group from 5-methyl-THF [12]. Both folate and 
vitamin B12 deficiency will decrease methionine forma­
tion which may result in decreased levels of »S-adeno- 
sylmethionine. In methylcobalamin deficiency, folate is 
trapped as 5-methyl-THF because methionine synthase 
is the only reaction able to convert 5-methyl-THF into 
THF (methy 1-folate trap) [13]. In such cases, a function­
al folate deficiency exists, although normal to increased
folate levels will be present in blood.
2.3. Requirements 
Humans are totally dependent on dietary sources o f  
folate, and major contributors are green leafy
be met by a variety of folate derivatives, as long as the 
essential structure of pteroylglutamic acid remains in­
tact [14], The inactivation of folate occurs after oxida­
tion and exposure to ultraviolet light and heat. Thus, 
naturally occurring folates are lost in storage and cook­
ing. Most naturally occurring folates are present as 
polyglutamates. This is in contrast to pharmaceutically 
available folate, which contains only monoglutamates. 
In the gut, monoglutamates are absorbed much faster 
than poly glutamates.
The demand o f folate is increased in infancy, adoles­
cence and pregnancy. The recommended dietary intakes 
for folate are presented in Table 1.
2.4. Diagnosis o f  folate deficiency
Folate deficiency leads to clinical symptoms such as di­
arrhoea, cheilosis and glossitis [15]. The haematological 
manifestations o f folate deficiency are macrocytosis, low 
reticulocyte, leucocyte and platelet count, anisocytosis, 
poikilocytosis, macroovalocytes and hypersegmentation 
of the nucleus of the neutrophils. Pathological cir­
cumstances, resulting in an increased folate requirement 
are: malabsorption due to sprue, restoration of blood cells 
after loss or haemolysis, alcohol abuse, treatment with 
folate antagonists (methotrexate) and antiepileptic drugs 
(phenytoin, phenobarbital, primidone).
Different methods are available for the measurement 
of folates. However, they are difficult to compare. Serum 
folate concentrations vary rather widely with respect to 
nutrition, sex, and the use of drugs. Folate is incorporated 
into red cells during erythropoiesis. Therefore, red cell 
polyglutamates reflect a more accurate and less variable 
index of folate status than serum folate levels [16]. Mor­
phologic blood examination showing hypersegmentation
of the polymorphonuclear leucocyte nucleus, used to be 
the best way to diagnose a folate deficiency [14]. Func­
tion tests to determine folate status include the de- 
oxyuridine suppression test and the FiGlu function test. 
Both methods are used to study folate levels indirectly.
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vegetables, liver and kidney. Requirements of folate can The deoxyuridine suppression test is based on the obser­
vation that, in case of folate deficiency, the uptake of 
tritiated thymidine by bone marrow cells is suppressed 
because of decreased folate-dependent conversion of 
DUMP into DTMP. The FiGlu function test is based on 
the increased urinary excretion of FiGlu after histidine 
loading, because folate deficiency leads to a decreased 
conversion of FiGlu into glutamic acid (Glu) (Fig. 3) [17]. 
In addition, folate deficiency will result in a mild to 
moderate hyperhomocysteinaemia. Therefore, the deter­
mination of the concentration of total homocysteine in
blood seems to be a valid indirect method, as well to diag­
nose a metabolic folate deficiency [18,19]. Microbiologic 
assays of folate depend upon the metabolic requirements 
of folate in certain microorganisms. Lactobacillus casei 
is generally accepted as the standard assay organism, be­
cause it responds to the greatest variety of different folate
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Fig. 3. Scheme of folate-mediated one-carbon transfer reactions (mod­
ified from Shane and Stokstad [64]).
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Table 1
Recommended dietary intake of folic acid (RD1) (modified from Health Council/Food and "Nutrition Council [62])
USA(RDA) UK FAO a/WHO b Netherlands
1990 /zg/day 1991 /ig/day /ig/day 1992 ¿tg/day
Male age > 19 years 200 200 200 200-300
Female age > 19 years 180 200 170 200-300
Pregnancy 400 300 >350 400-600
Lactation 280 260 270 400-600
aFAO: Food and Agriculture Organization 
bWHO: World Health Organization
derivatives [20]. A more sophisticated technique is the 
radioassay based on competitive binding of labelled and 
unlabelled folates to a limited number of binding sites on 
a folate-binding protein. The results are comparable to 
microbiologie assays. High performance liquid chroma­
tography (HPLC) separation of folates is favourable when 
specific folate derivatives need to be measured [20].
2.5. Genetic disorders of folate metabolism 
Up to now, five inherited disorders of folate metabo­
lism have been described. These are: (a) 5,10-methylene- 
THF reductase deficiency; (b) functional 5-methyl-THF- 
homocysteine methyltransferase (methionine synthase) de­
ficiency; (c) glutamate formiminotransferase deficiency;
(d) hereditary folate malabsorption; and (e) dihydrofolate 
reductase deficiency. Their clinical and biochemical 
characteristics are summarized in Table 2.
5,10-methylene-THFreductase deficiency. Mudd et al, 
[21] first described 5,10-methylene-THF reductase defi­
ciency. About 30 patients have been described (Fig. 3, 
conversion 4 and Table 2). The severity of the enzyme 
deficiency and the corresponding level of 5-methyl-THF 
parallels the clinical and biochemical symptoms. Clini­
cal symptoms are: generalized seizures, delayed 
psychomotor development and peripheral neuropathy. 
Severely affected patients often die at infancy or early 
childhood [22], Patients with milder symptoms tend to 
survive into adult life [21]. Their typical laboratory fea-
Table 2
Inherited defects in the metabolism of folate (modified from Rosenblatt [9]; Surtees and Leonard [57])
Characteristics MTHFR
Clinical
Megaloblastic anaemia
Developmental delay 
Seizures
Peripheral neuropathy 
Speech abnormality 
Apnoea
Gait abnormality
Biochemical data
Homocystinuria
Homocysteinaemia
Hypomethioninaemia
Low serum folate
Low red cel! folate
Low serum B !2
Increased MM A in urine
Increased FIGLU in urine
Enzyme deficiency detectable in
Treatment
+
+
+
+
+
+
+
+
+a
F,Le,Li,Ly
Betaine folic acid 
Methionine
Methionine synthase deficiency
Cbl E,G Cbl A,B Cbl C,D,F
+
+
+a
+
+
a
a
a
-H
+
+
+
+
+
F
Glutamic
formimino-transferase
deficiency
_ a
_ a
+
+
a
a
a
a
a
a
a
++
K, Li
Hydroxocobalamin, Folinic acid, Betaine Folic acid
Hereditary
folate
malabsorption
+
+
+
Li
Folic acid 
Folinic acid
+/- Clinical symptom or biochemical abnormality present/absent. 
a Exceptions described in some cases.
Cbl, cobalamin; FiGlu, formiminoglutamic acid; MMA, methylmalonic acid; MTHFR, 5,10-methylene-THF reductase deficiency; F, fibroblasts; 
K, kidney Le, leucocytes; Li, liver; Ly, lymphocytes.
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tures are given in Table 2. The enzyme defect is inherited 
in an autosomal recessive trait and can be assessed in liver, 
fibroblasts, lymphocytes and leukocytes. Kang et al. [23] 
recently discovered a ‘new variant’ of 5,10-methylene- 
THF reductase deficiency, which is characterized by the 
absence of neurological abnormalities, an enzyme activ­
ity of about 50% of the normal value, and distinctive ther­
molability of the enzyme in lymphocytes. Reportedly, the 
incidence of thermolabile 5,10-methylene-THF reductase 
was 5% in controls and 17% in patients with coronary
artery disease. This suggests a high mutated gene frequen­
cy among the general population. The mild 
hyperhomocysteinaemia assessed in some subjects with 
thermolabile 5,10-methylene-THF reductase was effective­
ly treated by oral folic acid therapy. Because severe 5,10- 
methylene-THF reductase deficiency is resistant to folate 
treatment, betaine is often prescribed.
Functional methionine synthase deficiency. Vitamin B |2 
as methylcobalamin is an essential cofactor for methionine 
synthase, and as adenosylcobalamin for the enzyme 
methylmalonyl-CoA mutase (EC 5.4.99.2). Therefore, an 
enzymatic disorder in the synthesis of these cobalamins 
will lead to a functional defect in methionine synthase or 
methylmalonyl-CoA mutase activity (Fig. 3, conversion 
5 and Table 2). The reported enzymatic defects may af­
fect either methylcobalamin synthesis (cobalamin E and 
G mutation), the synthesis of adenosylcobalamin 
(cobalamin A and B mutation), or both (cobalamin C, 
D and F mutation). The biochemical characteristics are
shown in Table 2.
Glutamate formiminotransferase deficiency. The enzyme 
glutamate formiminotransferase (EC 2.1.2.5) is involved 
in the catabolism of histidine (Fig. 3, conversion 9 and 
Table 2). This pathway may be present only in liver and 
kidneys, and represents, quantitatively, a minor single- 
carbon-pool, Glutamate formiminotransferase deficien­
cy syndrome, an autosomal recessively inherited disease, 
can be divided into two different phenotypes. The severe 
type is probably caused by a primary block in the 
cyclodeaminase enzyme (Fig. 3, conversion 10). These pa­
tients suffer from mental and physical retardation and 
cortical atrophy. The milder type of the disease may be 
due to a defect in the glutamate formiminotransferase 
enzyme (Fig. 3, conversion 9 and Table 2) without symp­
toms of mental retardation [9]. Folate, vitamin-Bi2 or 
serine treatment is hardly influencing biochemical symp­
toms such as FiGlu excretion and formiminoglutamic 
acidaemia. At present, the determination o f enzyme ac­
tivity is only possible in hepatocytes.
Defective folate absorption. An autosomal recessive in­
herited disorder in the absorption of folate was first 
described by Luhby et al. (Figs. 2 and 3, conversion 1 
and Table 2) [24]. About a dozen patients have been 
reported, who fail to absorb oral fo lic acid 
monoglutamates or reduced folates (food) [9,14]. These 
folate malabsorption disorders support the existence o f
a specific carrier mechanism in the transport of folate 
across the intestinal wall, and into the cerebrospinal fluid. 
The common clinical presentation in hereditary folate 
malabsorption is megaloblastic anaemia, diarrhoea, 
mouth ulcers, severe physical and mental retardation, and 
seizures in the first few months of life. Some patients re­
spond to treatment with very large doses o f folic acid 
monoglutamate (up to 40 mg/day). In others, the vitamin 
was successfully given intramuscularly. Some showed very 
low folate levels in the cerebrospinal fluid possibly due 
to a transport defect from the serum into the cerebrospinal 
fluid. Intramuscular treatment with reduced folates such 
as 5-formyl-THF (folinic acid (0Leucovorin)) can pro­
duce neurologic improvement [9].
Dihydrofolate reductase deficiency. A rare inherited dis­
order, dihydrofolate reductase deficiency, has been 
reported in three cases (Fig. 3, conversion 2). Depending 
on the degree of enzyme deficiency, this disease presents 
in infancy and may result in stillbirths and spontaneous 
abortions during reproductive life [25,26], Clinical symp­
toms of surviving infants are: failure to thrive, severe 
megaloblastic anaemia, glossitis, mental retardation and 
splenic enlargement. The diagnosis is based primarily on 
low hepatic levels of dihydrofolate reductase activity. 
Treatment with ®Leucovorin bypasses the enzyme block 
and corrects the defect.
3. Neural-tube defects
In 1952, Thiersch first suggested an association between 
NTDs and a maternal lack of folate, due to the prenatal 
use of folate antagonists [27]. Hibbard [17] reported a 
higher prevalence of birth defects in the offspring of 
folate-deficient mothers (3%), judged by an increased 
urinary excretion of FiGlu after histidine loading, com­
pared to controls (1.6%). However, the difference was not 
statistically significant and the malformations did not in­
clude NTDs. In 1965, Hibbard and Smithells reported a 
possible link between folate deficiency and the develop­
ment of human fetal malformations, in particular central 
nervous system malformations, including NTDs [28]. 
Their results suggested the presence o f an underlying 
defect of folate metabolism, such as a disturbance in folate 
absorption or turnover, possibly precipitated by the in­
creased demands of folate during pregnancy. This has 
been supported by Yates et al. [29] who demonstrated 
an association between maternal folate levels and NTD  
births, which could not be entirely explained by a lower 
intake of folate. Because the red cell folate levels in par­
ticular were lowest in mothers who had three or four pre­
vious NTD pregnancies, they hypothesized that a 
maternal genetic disorder of folate metabolism was re­
sponsible for the development of NTDs. The data 
reported by Kirke et al. [30] are in line with this. They 
found that maternal plasma folate and vitamin B12 lev­
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els, determined at the first antenatal visit, were indepen­
dent risk factors for having a child with a NTD.
The NTD prevalence in the products of spontaneous 
abortion is 10-fold increased as compared to the preva­
lence at birth [31]. Regarding this, it is of interest, that 
already in 1964, a possible relationship was demonstrated 
by Hibbard [17] between the occurrence of spontaneous 
abortion and folate deficiency.
As it can be concluded that a maternal shortage of 
folate during the periconceptional period may play a role 
in the development of NTDs, maternal folate supplemen­
tation in early pregnancy might therefore be a preven­
tive measure against the development of NTDs. Several 
observational studies have been carried out, most of which 
showed the protective effect of an increased maternal 
folate intake by dietary measures or tablets [32-36]. These 
studies have been extensively reviewed previously [1], 
Finally, the intervention studies, summarized and 
presented in Table 3, definitely proved the beneficial effect 
of an increased maternal folate intake in the periconcep­
tional period on the first occurrence and recurrence risk 
of NTDs [37-41],
Women taking antiepileptic drugs for the treatment of 
epilepsy have an increased risk of having an infant with 
a congenital malformation, particularly NTD [42]. Mead­
ow [43] speculated that the teratogenicity of antiepilep­
tic drugs may reside in the induction of folate deficiency . 
This is supported by the relationship between the use of 
antiepileptic drugs, folate levels and adverse pregnancy 
outcome, including spontaneous abortions and congenital 
malformations [44]. Antiepileptic drugs such as phéno­
barbital, phenytoin and primidone can reduce folate lev­
els by inhibiting intestinal absorption, or by increasing
folate turn-over due to induction of the cytochrome P- 
450 glucuronyl transferase enzymes [45,46]. The mater­
nal use of valproic acid and carbamazepine is considered 
to increase the risk of spina bifida in particular [47,48], 
For both antiepileptic drugs, no strong evidence is avail­
able for the presence of abnormally low serum folate lev­
els, but several studies report some form of interference 
with folate metabolism [49,50]. Recently, in mice, it has 
been demonstrated that valproic acid interferes with the 
conversion o f THF into 5-formyl-THF, which is possibly 
due to inhibition of the enzyme glutamate for- 
myltransferase, through which the teratogenicity of val­
proic acid may be explained by an altered folate 
metabolism [49],
In case a lack of maternal folate in early pregnancy 
predisposes to the development of NTDs, these malfor­
mations might be prevented by folic acid supplementa­
tion. Biale and Lewenthal [51] prescribed folic acid tablets 
to epileptic women using antiepileptic drugs and found 
a reduced risk of congenital malformations. However, 
there have been some criticisms regarding this study, i.e. 
historical controls were used, no tests of compliance were 
incorporated, and several women participated more than
once.
Although folate is generally accepted as non-toxic in 
man, high-dose folic acid supplementation may have 
several disadvantages. A high dose of folic acid (>  1.0 mg 
folic acid per day) may mask the haematologic effects of 
vitamin B12 deficiency, while its neurologic manifesta­
tions progress [52]. Possible risks of a high level of circu­
lating folate are noted by Scott and Weir [13]. Folic acid 
is a neurotoxin and causes convulsions in laboratory ani­
mals. Although the blood/brain barrier normally restricts
Table 3
Summary of intervention studies
Authors Design, Country Supplement per day3 Results Risk
reduction
Smithells et al. [32] Multicenter 
Non-rand omized 
Recurrence 
UK
Multivitamins + 0.36 mg folate 3 NTD/ 545 supplemented 
24 NTD/ 519 non-supplemented 
0 NTD/ 114 partially supplemented
86%
Vergei et al. [33] Non-randomized
Recurrence
Cuba
5.0 mg folate 0 NTD/ SI supplemented 
0 NTD I 20 partially supplemented 
4 NTD/ 114 non-supplemented
100%
Laurence et al, [34] Randomized
Recurrence
Wales
4.0 mg folate/placebo 2 NTD/ 60 supplemented 
4 NTD/ 51 placebo
58%
MRC Vitamin Study 
Research Group [35J
Multicenter 
Randomized 
Recurrence 
7 countries
4,0 mg folate/placebo 6 NTD/ 593 supplemented 
21 NTD/ 602 placebo
72%
CzeizeI and Dudàs [36] Randomized
Occurrence
Hungary
0.8 mg folate/placebo 0 NTD/ 2104 supplemented 
6 NTD/ 2052 placebo
100%
astarted at Jeast < 1 month before conception and continued through the 1 st trimester
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access of folic acid in such a way that very high doses 
are required to produce these effects, similar toxicity oc­
curs at much lower doses if the blood/brain barrier is 
damaged. In epileptic women, therefore, supplementation 
of folic acid with doses similar to that used in the MRC 
trial [40], might result in increased seizure frequency [53]. 
As the developed brain may be protected from the 
neurotoxic effects of synthetic folic acid by the 
blood/brain barrier, it is unknown whether neural tissue 
during very early embryonic development is protected.
A low dose of folic acid may also be favourable, as it 
is unclear whether a high-dose folate interferes with the 
transfer and metabolism of zinc in man, especially in cases 
with a marginal zinc status [54]. This may be important 
as dietary zinc deficiency and a relative shortage of ma­
ternal zinc has been associated with NTDs in human [55], 
Furthermore, the findings of Quinn et al. [56] suggest that 
in the presence of a zinc deficiency, the administration 
of high-dose folate increases the teratogenicity of such a 
deficiency. The enzyme, 7 -glutamyl hydrolase, converts 
polyglutamates to monoglutamates, which is an impor­
tant step in the absorption of folate. Its activity is zinc- 
dependent, which may be another regulatory mechanism 
in the availability of folate [57],
4. A possible biochemical explanation
As folate is an important substrate in the metabolism 
of homocysteine, it was suggested in 1991 that a subset 
of NTD might be due to a maternal disturbance in this 
metabolism, partly genically determined, in which folate 
plays a particularly important role [3].
The metabolism o f homocysteine is shown in Fig. 4. 
Methionine is an essential amino acid, present in eggs, 
meat and especially liver, which is converted to 
homocysteine. Homocysteine lies at a metabolic branch 
point, from which it may be transsulphurated to 
cystathionine or remethylated to reform methionine. 
The transsulphuration o f homocysteine to form cysta­
thionine is catalyzed by the enzyme, cystathionine syn­
thase, which is present in liver, skin fibroblasts, the 
central nervous system and lymfocytes. This enzyme re­
quires pyridoxine. The remethylation o f homocysteine 
back to methionine is enabled by two alternative reac­
tions, of which one is most important. It is the 
remethylation reaction by which the essential conver­
sion takes place o f folate as 5-methyltetrahydrofolate to 
tetrahydrofolate and, whereby vitamin B 12 as 
methylcobalamin acts as a cofactor. Apart from the en­
zymes concerned in folate conversion such as 5,10- 
methylenetetrahydrofolate reductase, another impor­
tant catalyzer in this reaction is the enzyme methionine 
synthase.
In case of a deficiency of folate as 5-methyl-THF, the 
remethylation of homocysteine is blocked, resulting in 
elevated homocysteine levels, which might be em-
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Fig, 4. Homocysteine metabolism in man [4]. (Source; Steegers- 
Theunissen et al. [4]. Reprinted by kind permission of Metabolism).
bryotoxic [58]. Such deficiency also leads to decreased 
methionine concentrations. Because methionine is an 
important donor of methyl-groups, which are essential 
in the methylation of D N A  and tRNA, decreased 
methionine levels, next to elevated homocysteine con­
centrations, might possibly disturb the development of 
the neural tube [59,60].
The circumstances causing a derangement in 
homocysteine metabolism, leading to increased blood 
levels of homocysteine and other metabolites, which 
might interfere with the closure of the neural tube are: 
deficiencies of cystathionine synthase, 5,10-methyl ene- 
THF reductase or 5-methyl-THF-homocysteine-methyl 
transferase, which is another name for the enzyme, 
methionine synthase; a lack of 5-methyl-THF, methyl­
cobalamin, or pyridoxal phosphate is supposed to result 
in increased homocysteine levels as high as found in car­
riers for the metabolic disease, homocystinuria. 
Therefore, apart from a direct influence of mild to se­
vere vitamin deficiencies on maternal, fetal and tropho­
blastic tissues, the indirect effect might be a moderate 
maternal hyperhomocysteinaemia. However, the possi­
ble effects of such a disorder on the course and outcome 
of pregnancy are, as yet, unknown.
Our studies, handling a possible relationship between 
a derangement of maternal homocysteine metabolism 
and the occurrence o f NTD, were performed in non­
pregnant women, who had given birth to an infant with 
a spina bifida or anencephalus, and a control group con­
sisting o f healthy non-pregnant women [3,4]. None of 
the women had been using vitamin preparations or oral 
contraceptives for a period of at least 3 months before
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the study was performed. The metabolism of homocys­
teine was studied by performing a standardized oral 
methionine loading test [4], In addition, vitamin levels, 
as well as biochemical parameters, were measured. The 
study was performed on the 21st day of the ovulatory 
cycle, because one of our previous studies showed 
changes in the metabolism of homocysteine during the 
normal ovulatory cycle [61]. The fasting homocysteine 
concentrations revealed to be lowest during the 
midluteal period, and therefore screening on a disorder 
in the metabolism of homocysteine is most sensitive dur­
ing this period of the cycle. Therefore, all studies were 
performed at the midluteal phase o f the cycle.
The results revealed that in 22% of the women, who 
had given birth to an infant with a NTD, methionine in­
tolerance was present after excluding folate and other vi­
tamin deficiencies, and liver or renal disturbances. 
Therefore, a maternal disorder in the metabolism of 
homocysteine strongly suggests being a risk factor for 
having an infant with anencephalus or spina bifida.
Because folate treatment without the existence of a 
folate deficiency increases the conversion of homocys­
teine into methionine, a certain percentage of the pre­
vention of NTDs, through folate supplementation, 
might be mediated by this beneficial effect upon 
homocysteine metabolism. Finally, to gain more infor­
mation about the association of maternal hyperhomo- 
cysteinaemia with the ocurrence of NTDs, we 
determined the homocysteine and relevant vitamin con­
centrations in amniotic fluid and blood of mothers car­
rying a child with a NTD, and compared those with a 
control group. Increased homocysteine levels in amnio­
tic fluid were found in women carrying a child with a 
NTD (Steegers-Theunissen et al, in press), which con­
firms the data of our previous study.
In future, further investigation is needed to study the 
possible toxic effects of increased homocysteine and 
decreased methionine levels on the formation of the neu­
ral tube. Apart from that, the remethylation enzymes, 
especially those involved in folate and vitamin B]2 me­
tabolism, have to be investigated in methionine- 
intolerant women. Then, we might be able to further 
prevent the occurrence o f these congenital malforma­
tions in the future,
5. Recommendations
At the beginning of this decade, two intervention 
studies definitely proved the beneficial effect of maternal 
folate supplementation to prevent the first occurrence 
and recurrence risk of a NTD-child [40,41]. Therefore, 
the Dutch Health Council as well as the Food and Nu­
trition Council were necessitated to launch new recom­
mendations with regard to the improvement of 
periconceptional maternal folate status [62]. The Dutch 
Council distinguishes between women who had had a
child with a NTD and therefore have a recurrence risk, 
and those who did not previously have a NTD-affected 
child and therefore have an occurrence risk. Women 
with a NTD family history, those who suffer from 
diabetes, or using drugs interfering with folate metabo­
lism and those who have a normal population risk are 
belonging to the latter category.
In order to significantly reduce the recurrence risk of 
a NTD-affected child, women are being advised to take 
a daily folate supplements of 4 -5  mg from at least 4 
weeks before conception until at least 8 weeks after con­
ception. This should be done under medical supervision. 
It is recommended that women with an occurrence risk 
should take care of a daily folate intake of 400 fig from 
at least 4 weeks before conception until at least 8 weeks 
after conception, The consumption of foods which are 
rich in folate is encouraged in order to reach this level 
Introduction as soon as possible, of foods which have 
been fortified or restored with folate, is also recom­
mended. The choice of foods to which folate has been 
enriched and the amount added should be such that 
there is as little chance as possible of an intake in excess 
of 1 mg/day, If the introduction of such food-products 
cannot be achieved within a reasonable period of time, 
women are advised to take one 400 fig folate tablet daily,
The proposed measures to increase folate intake will 
have to be evaluated after a certain period, in order to 
determine their effect on public health.
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